5.71

2.88% 0.16

After Hours: 5.73 0.02 +0.35%

Opus Genetics Inc (IRD)

Overview News Price History Discussions Forecast

Opus Genetics Inc stock is traded at $5.71, with a volume of 691.50K. It is up +2.88% in the last 24 hours and up +13.52% over the past month. Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

Previous Close:

$5.55

Open:

$5.57

24h Volume:

691.50K

Relative Volume:

0.74

Market Cap:

$406.26M

Revenue:

$14.20M

Net Income/Loss:

$-49.59M

P/E Ratio:

-6.7783

EPS:

-0.8424

Net Cash Flow:

$-35.25M

1W Performance:

+10.87%

1M Performance:

+13.52%

6M Performance:

+185.50%

1Y Performance:

+611.97%

1-Day Range:

$5.40

$5.75

1-Week Range:

$5.0744

$5.75

52-Week Range:

$0.7101

$5.75

Opus Genetics Inc Stock (IRD) Company Profile

Name

Opus Genetics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

248-681-9815

Address

8 DAVIS DRIVE, DURHAM

Employee

Twitter

Next Earnings Date

2026-03-30

Latest SEC Filings

IRD's Discussions on Twitter

Compare IRD vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IRD Opus Genetics Inc	5.71	394.88M	14.20M	-49.59M	-35.25M	-0.8424
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Opus Genetics Inc Stock (IRD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-30-26	Initiated	Cantor Fitzgerald	Overweight
Mar-16-26	Initiated	Oppenheimer	Outperform
Jan-20-26	Initiated	BTIG Research	Buy
Dec-10-25	Initiated	B. Riley Securities	Buy
Nov-25-25	Initiated	Piper Sandler	Overweight
Oct-29-25	Initiated	Wedbush	Outperform
Oct-16-25	Initiated	Chardan Capital Markets	Buy
Apr-11-25	Initiated	Craig Hallum	Buy
Nov-13-24	Resumed	H.C. Wainwright	Buy

View All

Opus Genetics Inc Stock (IRD) Latest News

Apr 15, 2026

Ideas Watch: What is the earnings history of Opus Genetics IncPortfolio Return Report & Reliable Entry Point Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

Night Vision Disturbances Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Opus Genetics, Viatris, Nevakar, Vyluma, Pfizer, Allergan, AbbVie - Barchart.com

Apr 10, 2026

Night Vision Disturbances Pipeline 2026: MOA, ROA, - openPR.com

Apr 10, 2026

Opus Genetics to Present Key Ophthalmology Research at ASCRS Annual Meeting 2026 - Quiver Quantitative

Apr 10, 2026

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - Bitget

Apr 10, 2026

Apr 09, 2026

Profit Review: Is Opus Genetics Inc in a consolidation phase2026 Technicals & Community Verified Trade Signals - baoquankhu1.vn

Apr 09, 2026

Opus Genetics Receives 'Moderate Buy' Rating from Analysts - National Today

Apr 09, 2026

Opus Genetics Enters Strategic Financing Agreement With Oberland Capital - VisionMonday.com

Apr 09, 2026

Apr 08, 2026

Forecast Cut: Will Opus Genetics Inc be affected by tariffsWeekly Investment Summary & Growth Focused Entry Point Reports - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Opus Genetics, Inc. (R3X1.F) stock price, news, quote and history - Yahoo Finance UK

Apr 07, 2026

Opus Genetics enters change in control bonus agreements with key executives - Investing.com India

Apr 07, 2026

Opus Genetics enters change in control bonus agreements with key executives By Investing.com - Investing.com Australia

Apr 07, 2026

BTIG Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo

Apr 07, 2026

Opus Genetics Adopts Change-in-Control Executive Bonus Agreements - TipRanks

Apr 07, 2026

Opus Genetics Secures Up to $155 Million in Non-Dilutive Funding from Oberland Capital to Advance Gene Therapy Pipeline for Inherited Retinal Diseases - Minichart

Apr 07, 2026

Opus Genetics (NASDAQ: IRD) adds change-in-control tax reimbursements - Stock Titan

Apr 07, 2026

Opus Genetics Secures Major Non-Dilutive Funding Facility - TipRanks

Apr 07, 2026

Opus Genetics Secures Up to $155 Million Notes and Raises $5 Million in Equity Financing - TradingView — Track All Markets

Apr 07, 2026

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital - Bitget

Apr 07, 2026

Pullback Watch: How does Opus Genetics Inc correlate with Nasdaq2026 Trends & AI Driven Stock Reports - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Chardan Capital Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - MSN

Apr 06, 2026

Opus Genetics (IRD) lands $155M Oberland deal to fund gene therapy pipeline - Stock Titan

Apr 06, 2026